IP Library Granted Patent US 9,187,539
Granted Patent B2
US 9,187,539 · App. 13/975,168 · Granted Nov 17, 2015

Compositions having antiangiogenic activity and uses thereof

Inventors: Aleksander S. Popel (Lutherville, MD); Emmanouil D. Karagiannis (Cambridge, MA)
Assignee: The Johns Hopkins University
C07K14/47C07K14/472C07K14/475C07K14/78C12N9/6421C12N9/6489
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,187,539
App. No.
13/975,168
Granted
Nov 17, 2015
Kind
B2
Abstract

Compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators are described. As discussed in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators of angiogenesis that have been characterized in vitro and/or in vivo.

Claims (21)

1. An isolated peptide or analog thereof consisting of a sequence having at least 85% amino acid sequence identity to:

Properdin:

(SEQ ID NO: 49)

GPWEPCSVTCSKGTRTRRR;

or

Fibulin-6:

(SEQ ID NO: 44)

QPWGTCSESCGKGTQTRAR,

wherein the peptide comprises at least one modification.

2. A peptide conjugate comprising the peptide of claim 1 conjugated to an agent that specifically binds a tumor marker or endothelial cell marker.

3. A pharmaceutical composition comprising an effective amount of an isolated peptide of claim 1 in a pharmacologically acceptable excipient.

4. A pharmaceutical composition comprising i) an isolated polypeptide having an amino acid sequence set forth in SEQ ID NO: 49 or SEQ ID NO: 44, and ii) one or more peptides of SEQ ID Nos. 1-43, 45-48, and 50-156.

5. An isolated peptide or analog thereof consisting of a sequence having at least 85% amino acid sequence identity to:

Properdin: GPWEPCSVTCSKGTRTRRR(SEQ ID NO: 49);

Or

Fibulin-6: QPWGTCSESCGKGTQTRAR (SEQ ID NO: 44), wherein the peptide is conjugated to an agent that specifically binds a tumor marker or endothelial cell marker.

6. The isolated peptide or analog there of claim 1 , wherein the modification is a sequence alteration or post-translational modification that increases protease resistance, biodistribution, or therapeutic efficacy.

7. A method of reducing blood vessel formation in a tissue or organ the method comprising:

(a) contacting the tissue, or organ with a vector encoding the polypeptide of claim 1 ; and

(b) expressing the polypeptide in a cell of the tissue or organ, thereby reducing blood vessel formation in the tissue or organ.

8. A method for decreasing blood vessel formation in a subject in need thereof, the method comprising administering an effective amount of the peptide of claim 1 to the subject, thereby decreasing blood vessel formation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2020
From: POPEL, ALEKSANDER P.; KARAGIANNIS, EMMANOUIL D.
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 052499/0607 →
CONFIRMATORY LICENSE Recorded Oct 27, 2017
From: JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044309/0541 →
Continuity (4)
Division 13369240 · Feb 8, 2012
Division 11992001
Provisional Application 60716341 · Sep 12, 2005
Related Publication 20140045757A1 · Feb 13, 2014